Home/Filings/4/0001689548-26-000013
4//SEC Filing

Sniecinski Megan 4

Accession 0001689548-26-000013

CIK 0001689548other

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 5:50 PM ET

Size

9.0 KB

Accession

0001689548-26-000013

Insider Transaction Report

Form 4
Period: 2026-01-08
Sniecinski Megan
Chief Operating Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-01-08+9,62530,502 total
  • Tax Payment

    Common Stock

    [F2]
    2026-01-10$288.45/sh1,087$313,54529,415 total
  • Award

    Stock Option (Right to Buy)

    [F3]
    2026-01-08+7,7007,700 total
    Exercise: $294.38Exp: 2036-01-08Common Stock (7,700 underlying)
Footnotes (3)
  • [F1]Ms. Sniecinski was awarded 9,625 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
  • [F2]Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.
  • [F3]The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.
Signature
/s/ Alex Nemiroff, as Attorney-in-Fact|2026-01-12

Issuer

Praxis Precision Medicines, Inc.

CIK 0001689548

Entity typeother

Related Parties

1
  • filerCIK 0001781480

Filing Metadata

Form type
4
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 5:50 PM ET
Size
9.0 KB